Xilio re­ports hand­ful of re­spons­es for com­bo in col­orec­tal can­cer

Xilio Ther­a­peu­tics said its an­ti-CT­LA-4 pro­duced promis­ing ini­tial da­ta in cer­tain col­orec­tal can­cer pa­tients en­rolled in a mid-stage tri­al. But the drug’s fu­ture is un­cer­tain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER